A scientific discussion of the safety and efficacy of gene therapy products may be academic as the issue of regulatory oversight of gene therapy clinical trials has become a political mud pit.

Indeed, the politicalization of gene therapy is now so complete that the NIH's Recombinant DNA Advisory Committee (RAC) has decided to put on its agenda a proposal by anti-biotech activist Jeremy Rifkin that would basically halt approvals of virtually all gene therapy trials using viral vectors.